Ingevity Corp. recently announced it has completed its acquisition of the Capa™ caprolactone division of Perstorp Holding AB for a cash purchase price of €578.9 million ($652.5 million).
Ingevity will reportedly include the business in its Performance Chemicals segment and report revenues as Engineered Polymers.
“The Capa division is a strong, market-leading business focused on high-growth end-use applications and is an excellent fit with Ingevity’s business model and capabilities,” said Michael Wilson, Ingevity president and CEO. “We are very pleased to be adding such a unique business to our company; one that will provide new avenues for strategic growth. Moreover, we’re excited to welcome our new employees in Warrington and across the globe.”